جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

6 مُخرَج نتائج البحث عن «Programmed cell death»

مقالوصول مغلق2026

Elucidating the mechanism of ADAM10/PD-L1 interaction in pancreatic adenocarcinoma cell lines using cellular and computational analyses

Journal of Biomolecular Structure and Dynamics · مجلد 44 (16) · 7537-7551

Targeting the immune checkpoint programmed cell death-ligand 1 (PD-L1) faces diverse challenges against pancreatic ductal adenocarcinoma (PDAC), the most common type of cancer-related death. Shedding of PD-L1 from the tumor cell surface by A Disintegrin And Metalloprotease 10 (ADAM10) may impede the function of antitumor immune cells. Understanding the molecular mechanisms behind this interaction is urgently needed. This study elucidates the mechanism of ADAM10/PD-L1 interaction in the pancreatic adenocarcinoma cell line, PANC-1, using cellular assays, molecular docking, and molecular dynamics (MD) simulations. Cellular assays validated that ADAM10 interacts with PD-L1 and sheds the PD-L1 from the cell surface, generating soluble PD-L1 (sPD-L1). Concurrently, the docking results identified critical residues and potential contact points, providing strong evidence for a stable and specific interaction between ADAM10 and PD-L1. The molecular dynamics (MD) simulations further confirmed the structural integrity of the ADAM10/PD-L1 complex, predicting its compactness and stability. These results elucidate how ADAM10 recognizes and interacts with PD-L1, facilitating its cleavage. Future work can leverage these findings to develop potent cancer immunotherapies that inhibit the ADAM10/PD-L1 interaction and the generation of soluble molecules.

ADAM10PD-L1pancreatic ductal adenocarcinomaprotein-protein interaction
مراجعةمفتوح (مستودع)20259استشهاد· Semantic Scholar

Anticancer Potential of Wogonin: A Comprehensive Treatise

Food Science & Nutrition · مجلد 13 (11) · e71128-e71128

Georgi. It has been recognized as an active phytochemical with specific therapeutic potential and significant pharmacological effects, especially in cancer research. Nevertheless, increasing preclinical data both in vitro and in vivo demonstrate its effectiveness against a broad spectrum of cancers, including breast, ovarian, lung, gastric, colorectal, prostate, renal, glioblastoma, and hematological types. Wogonin exerts its anticancer effects through a complex mechanism that involves the induction of programmed cell death (apoptosis), autophagic modulation, and cell cycle arrest. It also suppresses angiogenesis of tumors, epithelial-mesenchymal transition (EMT), invasion, metastasis, and multidrug resistance effects. The effects are supported by the compound's ability to regulate a variety of oncogenic and tumor-suppressive signaling pathways, particularly PI3K/Akt, STAT3, NF-kB, MAPK, AMPK, and Wnt/beta-catenin. It modulates apoptosis-related proteins (Bax, Bcl-2, PARP, caspases) and transcription factors. Wogonin has been shown to enhance the antitumor effects of established chemotherapeutic agents, and it works synergistically with these drugs in multiple cancer models, with the added benefits of reduced systemic toxicity. Nevertheless, it has poor oral bioavailability and water solubility, which limits its clinical application. Recent advances in nanocarriers and liposomal delivery systems show promise in overcoming pharmacokinetic challenges. This review consolidates available pharmacological, mechanistic, and pharmacokinetic evidence of wogonin, highlights its potential in combination therapies, and identifies research gaps and formulation strategies necessary for advancing this candidate towards clinical development as a novel anticancer agent.

wogoninanticancer activityflavonoidsapoptosis
مقالوصول مفتوح20256استشهاد· Semantic Scholar

Parthanatos drives cognitive decline in repeated brain trauma: MSC-derived exosomes as a novel therapeutic strategy

Frontiers in Pharmacology · مجلد 16 · 1622018-1622018

Introduction: Repetitive traumatic brain injury (RTBI) represents a cumulative neurological insult associated with progressive neurodegeneration and limited therapeutic options. In this study, we uniquely evaluate the neuroprotective potential of mesenchymal stem cell (MSC)-derived exosomes in a rat model of RTBI, an area scarcely explored. Methods: RTBI was induced via a controlled mechanical impact to the skull once every day for 5 days. MSC-derived exosomes were administered 24 h after the final insult in two paradigms: a single dose (MSC-Ex1) with 2 weeks of follow-up, and a dual dose (MSC-Ex2) given 1 week apart, with sacrifice 1 week later. Rats were assigned to four groups: control, RTBI, RTBI + MSC-Ex1, and RTBI + MSC-Ex2. Results: MSC-derived exosome regimens comparably restored cognitive performance in the Novel Object Recognition and Y-maze tests. While both treatment paradigms preserved cortical histoarchitecture, the double-dose regimen led to a more pronounced restoration compared to the moderate tissue recovery observed in the single-dose group. Crucially, this work identifies parthanatos inhibition as a novel mechanistic axis for MSC-derived exosomes-mediated neuroprotection. MSC-derived exosomes attenuated excitotoxicity and oxidative stress, quelling the parthanatos cascade by suppressing PARP1, PAR polymers, nuclear AIF and MIF, as well as calpain, key executors of this caspase-independent cell death pathway. Additionally, MSC-derived exosomes normalized cyclophilin B and Hsp70 levels, suggesting their compensatory role in modulating the endogenous stress response. Conclusion: Overall, these findings demonstrate that MSC-derived exosomes counteract RTBI-induced neurodegeneration through multifaceted mechanisms, with parthanatos suppression at the core. Importantly, the dual-dosing regimen conferred no significant benefit over the single dose, highlighting the therapeutic promise of early intervention. This study positions MSC-derived exosomes as a novel, cell-free therapy capable of intercepting RTBI-induced neuropathology by targeting an under recognized form of programmed cell death.

repetitive traumatic brain injuryparthanatosmesenchymal stem cell-derived exosomescognitive decline
مقالوصول مفتوح202350استشهاد· Semantic Scholar

Anticancer and apoptosis inducing potential of quercetin against a wide range of human malignancies

International Journal of Food Properties · مجلد 26 (1) · 2590-2626

Quercetin, a flavonoid, is a dietary component that has attracted the attention of dietitians and medicinal chemists due to its anticancer potential. It is an antioxidant that has a significant role in reducing different human cancers such as breast, pancreatic, prostate, colon, blood, and oral. Being as an additional anti-cancer agent, it can stop cancer cell invasion and metastasis, induce apoptosis and autophagy, decrease cancer cell growth and proliferation. Multiple mechanisms, including suppression of pathways involved in cell survival, angiogenesis, and inflammation, are thought to be responsible for these anticancer effects. Quercetin has anti-inflammatory properties in both in vitro and in vivo tests, which is important as chronic inflammation is a major contributor to cancer. Preventing the synthesis of cytokines and chemokines that encourage inflammation can support to lessen inflammation and stop the spread of cancer. In cancer cells, quercetin can cause programmed cell death, which can stop the cells from rapidly multiplying and replicating. It provides protection against degradation of DNA induced by radiation and other carcinogens. The PI3K/Akt/mTOR pathway, the NF-κB system, and the Wnt/β-catenin pathway is few of the signaling pathways that quercetin modulates. It can activate the process of autophagy, which breaks the growth and range of cancer by having cells terminate and recover damaged or unwanted cellular mechanisms. The best treatment plans for various cancer kinds will need to be determined through additional research, which will also help confirm its safety and effectiveness in humans.

quercetinflavonoidsanticancer activityapoptosis
مقالمفتوح (مستودع)202341استشهاد· Semantic Scholar

Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies

Journal of Biomolecular Structure and Dynamics · مجلد 41 (21) · 11535-11550

A new set of quinoline and isatine derivatives were synthesized as antiangiogenic VEGFR-2 inhibitors. On a biological level, the in vitro ability of the obtained candidates to inhibit VEGFR-2 was found to be strong with IC50 values in the range of 76.64–175.50 nM. To investigate the cytotoxicity and safety, all compounds were tested against a panel of four cancer cell lines (A549, Caco2, HepG2 and MDA) as well as two normal cell lines (Vero and WI-38). Interestingly, compound 12 exhibited noticeable cytotoxicity against A549, Caco2 and MDA with IC50 values of 5.40, 0.58 and 0.94 µM, respectively. These results were better and comparable to that of doxorubicin (0.70, 0.82 and 0.90 µM, respectively) with more than three folds higher selectivity index against the Caco2 cell lines. Compound 9 prevented the healing of the cancer cells at a low concentration. Also, the compound’s potential to induce programmed cell death in Caco-2 was proved through the significant down regulating of the expression of Bcl2, Bcl-xl and Survivin in addition to the slight upregulation of the TGF-β gene. The cell cycle analysis indicated that compound 9 arrested the Caco-2 cells in the G2/M phase. Interestingly, the molecular docking studies against VEGFR-2 revealed the correct binding of the targeted compounds similar to sorafenib. Furthermore, MD experiments validated the binding of compound 12 with VEGFR-2 over 100 ns, as well as MM-PBSA analysis that confirmed the precise binding with optimum energy. Finally, ADMET analysis showed the general drug-likeness and confirmed the safety of the tested compounds.Communicated by Ramaswamy H. Sarma

quinoline derivativesVEGFR-2 inhibitorsangiogenesis inhibitorsantiproliferative activity
مقالمفتوح (مستودع)202320استشهاد· Semantic Scholar

Clinicopathological Significance and Expression Pattern of Bcl2 in Breast Cancer: A Comprehensive in silico and in vitro Study

Saudi Journal of Biological Sciences · مجلد 31 (2) · 103916-103916

B-cell lymphoma/leukemia gene-2 (Bcl-2) is the primary proto-oncogene that has been shown to work by preventing apoptosis/programmed cell death. Bcl-2 combines a variety of cell-generated signals associated to the survival and death of cells. In glioma, lung, and breast cancer, Bcl-2 over-expression has been linked to an increase in invasion and migration. Many treatment regimens that target BCL2 have been established and approved, and thus increasing the survival rates of the patients. The primary goal of this research was to recognize new therapeutic compounds that target BCL2 and assess BCL2 expression pattern in BC patients. We used various bioinformatic tools as well as several in vitro assays to look out the expression and inhibition of Bcl2 in BC. Our study shows that BCL2 had a strong connection with tumour stroma, notably with suppressor cells originating from myeloid tissues. Moreover, in vitro and in silico research identified Paclitaxel as a promising natural substance that targets BCL2. Overall, this work shows that BCL2 overexpression accelerates the development of BC, and that targeting BCL2 in conjunction with other drugs will dramatically improve BC patient’s response to treatment and prevent the emergence of drug resistance.

Bcl-2breast cancerapoptosistumor stroma